Takahashi Hiroaki, Yaegashi Yukiko, Saito Yoko, Nihei Satoru, Tairabune Tomohiko, Ujiie Haruki, Asaka Junichi, Kudo Kenzo
Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, 1-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3694, Japan.
Department of Pharmacy, Iwate Medical University Hospital, 2-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3695, Japan.
J Pharm Health Care Sci. 2022 Sep 1;8(1):22. doi: 10.1186/s40780-022-00253-y.
We previously reported that high body weight was a risk factor affecting the onset of anti-epidermal growth factor receptor (EGFR) antibody drug-induced acneiform rash. The current study investigated the relationship between risk factors for anti-EGFR antibody drug-induced acneiform rash and survival probability in colorectal cancer patients, as well as effects of drug withdrawal, dose reduction, or treatment discontinuation on treatment continuation.
This retrospective study included 67 patients with unresectable advanced or recurrent colorectal cancer treated with anti-EGFR antibody drugs for the first time.
The survival time and acneiform rash grade of patients with high body weight (≥ 67.2 kg) were significantly longer and higher than those of patients with low body weight (< 67.2 kg). Moreover, the treatment continuation time of patients with drug withdrawal or dose reduction was significantly longer than that of patients without drug withdrawal or dose reduction or with/without treatment discontinuation. Meanwhile, the treatment continuation time of patients with treatment discontinuation was significantly shorter than that of patients with drug withdrawal or dose reduction or those without drug withdrawal, dose reduction, or treatment discontinuation.
High body weight is a novel prognostic factor for patients receiving cancer drugs with anti-EGFR antibody drugs. Hence, the results of this study suggest that patients with high body weight should be carefully monitored for the development of acneiform rash when receiving anti-EGFR antibody drugs as cancer drug therapy.
我们之前报道过，高体重是影响抗表皮生长因子受体（EGFR）抗体药物诱发痤疮样皮疹发生的一个风险因素。本研究调查了抗EGFR抗体药物诱发痤疮样皮疹的风险因素与结直肠癌患者生存概率之间的关系，以及停药、减量或中止治疗对治疗持续时间的影响。
这项回顾性研究纳入了67例首次接受抗EGFR抗体药物治疗的不可切除的晚期或复发性结直肠癌患者。
高体重（≥67.2千克）患者的生存时间和痤疮样皮疹分级显著长于和高于低体重（<67.2千克）患者。此外，停药或减量患者的治疗持续时间显著长于未停药或未减量或未中止治疗的患者。同时，中止治疗患者的治疗持续时间显著短于停药或减量患者或未停药、未减量或未中止治疗的患者。
高体重是接受含抗EGFR抗体药物的癌症药物治疗患者的一个新的预后因素。因此，本研究结果表明，接受抗EGFR抗体药物作为癌症药物治疗的高体重患者在出现痤疮样皮疹时应受到密切监测。
